M Roh Selected Research

Therapeutics

4/2012	Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells.
11/2007	A Phase II safety and effect on time to tumor progression study of intratumoral light infusion technology using talaporfin sodium in patients with metastatic colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Roh Research Topics

Disease

3	Neoplasms (Cancer) 04/2012 - 11/2007
2	Carcinoma (Carcinomatosis) 01/2012 - 04/2010
1	Necrosis 02/2014
1	Inflammation (Inflammations) 02/2014
1	Retinal Degeneration 02/2014
1	Prostatic Neoplasms (Prostate Cancer) 04/2012
1	Adenocarcinoma 04/2010
1	Carcinogenesis 04/2010
1	Neoplasm Metastasis (Metastasis) 11/2007
1	Colorectal Neoplasms (Colorectal Cancer) 11/2007
1	Genetic Predisposition to Disease (Genetic Predisposition) 11/2006
1	Acne Vulgaris 11/2006
1	Hyperplasia 04/2001
1	Herpes Zoster 04/2000

Drug/Important Bio-Agent (IBA)

3	Phosphotransferases (Kinase)IBA 02/2014 - 04/2010
1	Interleukin-6 (Interleukin 6)IBA 02/2014
1	Receptor-Interacting Protein Serine-Threonine KinasesIBA 02/2014
1	HMGB1 Protein (HMG1)IBA 02/2014
1	SynaptophysinIBA 04/2010
1	Androgen Receptors (Androgen Receptor)IBA 04/2010
1	thiamine triphosphorate (TTP)IBA 11/2007
1	Talaporfin (talaporfin sodium)IBA 11/2007
1	Pharmaceutical PreparationsIBA 11/2007
1	XenobioticsIBA 11/2006
1	ErbB Receptors (EGF Receptor)IBA 04/2001
1	LigandsIBA 04/2001
1	Transforming Growth Factor alpha (TGF-alpha)IBA 04/2001
1	Epidermal Growth Factor (EGF)IBA 04/2001
1	Proteins (Proteins, Gene)FDA Link 04/2000
1	Guanylate KinasesIBA 04/2000

Therapy/Procedure

2	Therapeutics 04/2012 - 11/2007
1	Lasers (Laser) 01/2012